Havana, Mar 20, (RHC), -- Heberprot-P, a safe and effective drug, developed in Cuba for the treatment of complex diabetic foot ulcers, has successfully reached the markets of 20 countries, said Luis Herrera, director of the Center for Genetic Engineering and Biotechnology (CIGB).
According to the expert, Heberprot-P has met sanitary regulations in Ecuador, Belarus, Argentina, Brazil, Russia, Venezuela and Ukraine.
Russia, a country with a high regulatory standard, belonging to the BRICS bloc that also includes Brazil, India, China and South Africa, recently approved the use of the Cuban drug, following strict inspections of its scientific foundations and production process.
Globally, more than 145,000 patients have used it for treatment, Herrera added. Many countries, including China, have been conducting advanced stage-three tests of the drug.
He said the Heberprot-P therapy, applied in the form of injections, has revolutionized the treatment for diabetes and disruptions of the body's natural self-repair mechanism which often lead to amputations of the lower limbs.
